文献速递瓣膜外科先天性心脏病外科

先天性二尖瓣发育不良手术后长期结局

Long-term outcomes after surgical management of congenital mitral valve dysplasia.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-08-26

该回顾性研究分析了1975至2024年间因严重先天性二尖瓣发育不良接受手术的102例患者,中位年龄10个月。10年和20年总体生存率分别为86.8%和78.2%,Shone复合征是唯一与生存降低相关的因素。初次修复后残留二尖瓣反流程度显著影响修复耐久性,但初始修复与置换策略的长期生存无显著差异。

要点

  • Shone复合征是唯一与生存降低相关的因素(P=.018)。
  • 年龄<1岁、Shone复合征、混合性二尖瓣病变、吊床瓣或降落伞瓣与更高MVR率相关(P<.05)。
  • 初次修复后残留MR程度显著影响修复耐久性(P=.001)。

核心结论

  • 先天性二尖瓣发育不良手术后总体长期结局良好,但Shone复合征患者风险更高。
  • 二尖瓣置换仍常见,尤其在婴儿、复杂解剖及修复后残留病变者中。

研究设计与样本

  • 回顾性队列研究,纳入1975至2024年单中心因严重先天性二尖瓣发育不良(吊床瓣、降落伞瓣及相关表型)接受手术的全部患者。
  • 共102例患者,中位年龄10个月(IQR 6-30),接受187次手术,中位随访11.5年(IQR 9.11-15.5)。

主要发现

  • 10年和20年总体生存率分别为86.8%(95% CI 78.3%-92.1%)和78.2%(95% CI 64.7%-87.1%)。
  • Shone复合征是唯一与生存降低相关的因素(P=.018)。
  • 年龄<1岁、Shone复合征、混合性二尖瓣病变、吊床瓣或降落伞瓣与更高MVR率相关(P<.05)。
  • 初次修复患者(n=85)中,10年MVR累积发生率:无/微量残留MR为0%,轻度残留MR为22.6%(95% CI 11.1%-46.0%),中度/重度残留MR为52.1%(95% CI 38.9%-69.8%)(P=.001)。
  • 初始修复与置换策略的长期生存无显著差异。

关键数值与推荐

  • 严重先天性二尖瓣发育不良包括吊床瓣、降落伞瓣及相关表型。
  • 残留MR程度分级:无/微量、轻度、中度/重度。

临床怎么用

  • 对先天性二尖瓣发育不良患者应关注Shone复合征,因其与生存降低相关。
  • 初次修复时应尽量优化技术以减少残留MR,因残留MR程度显著影响修复耐久性。
  • 婴儿及复杂解剖患者需警惕较高的二尖瓣置换风险。

局限性

  • 样本量较小(102例),部分亚组分析可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate long-term survival and durability after congenital mitral valve dysplasia (CMVD) surgery and identify factors associated with mortality and mitral valve replacement (MVR). METHODS: All patients undergoing surgery for severe forms of CMVD (hammock, parachute, and related phenotypes) at our center between 1975 and 2024 were retrospectively reviewed. Survival was estimated using Kaplan-Meier methods. Time to MVR was analyzed using cumulative incidence accounting for competing risks. RESULTS: A total of 102 patients (median age, 10 months; [interquartile range, 6-30]) underwent 187 procedures, with a median follow-up of 11.5 years [interquartile range, 9.11-15.5]. Overall survival at 10 and 20 years were 86.8% (95% CI, 78.3%-92.1%) and 78.2% (95% CI, 64.7%-87.1%), respectively. Shone complex was the only factor associated with reduced survival (P = .018). Age <1 year, Shone complex, mixed mitral disease, and hammock valve or parachute valve were associated with greater rates of MVR (P < .05). Among patients undergoing primary repair (n = 85), residual mitral regurgitation (MR) strongly impacted repair durability, with a 10-year cumulative incidence of MVR of 0% with none/trivial residual MR, 22.6% (95% CI, 11.1%-46.0%) with mild residual MR, and 52.1% (95% CI, 38.9%-69.8%) with moderate/severe residual MR (P = .001) Long-term survival did not differ significantly between initial repair and replacement strategies. CONCLUSIONS: Overall long-term outcomes after MV surgery for CMVD are favorable although diminished by the greater-risk profile of patients with Shone complex. MVR remains frequent, particularly in infants and complex anatomies, and when residual lesions persist after repair. These findings support the need for improved reconstructive techniques and innovative replacement options in selected patients.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Provost B, Weixler V, Fournier E, et al. Long-term outcomes after surgical management of congenital mitral valve dysplasia. J Thorac Cardiovasc Surg. 2026. PMID: 42648538. doi:10.1016/j.jtcvs.2026.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。